CLONAZEPAM Drug Patent Profile

Which patents cover Clonazepam, and when can generic versions of Clonazepam launch?

Clonazepam is a drug marketed by Alembic, Barr, Ph Health, Sun Pharm Inds Inc, Accord Hlthcare, Actavis Elizabeth, Aurobindo Pharma Usa, Chartwell Rx, Pharmobedient, Prinston Inc, Rubicon Research, Sandoz, Teva, and Watson Labs. and is included in sixteen NDAs.

The generic ingredient in CLONAZEPAM is clonazepam. There are ten drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the clonazepam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Clonazepam

A generic version of CLONAZEPAM was approved as clonazepam by TEVA on September 10^th, 1996.

Summary for CLONAZEPAM

US Patents:	0
Applicants:	14
NDAs:	16
Finished Product Suppliers / Packagers:	30
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	69
Patent Applications:	4,526
Drug Prices:	Drug price information for CLONAZEPAM
Drug Sales Revenues:	Drug sales revenues for CLONAZEPAM
DailyMed Link:	CLONAZEPAM at DailyMed

See drug prices for CLONAZEPAM

See drug sales revenues for CLONAZEPAM

Recent Clinical Trials for CLONAZEPAM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Sao Paulo General Hospital	PHASE4
Centro de Atencion e Investigacion Medica	PHASE4
Beni-Suef University	NA

See all CLONAZEPAM clinical trials

Pharmacology for CLONAZEPAM

Drug Class

Benzodiazepine

Medical Subject Heading (MeSH) Categories for CLONAZEPAM

Anticonvulsants

GABA Modulators

Anatomical Therapeutic Chemical (ATC) Classes for CLONAZEPAM

N03AE	Benzodiazepine derivatives
N03A	ANTIEPILEPTICS
N03	ANTIEPILEPTICS
N	Nervous system

US Patents and Regulatory Information for CLONAZEPAM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rubicon Research	CLONAZEPAM	clonazepam	TABLET;ORAL	075468-003	Oct 6, 2000	AB	RX	No	No
Chartwell Rx	CLONAZEPAM	clonazepam	TABLET;ORAL	074925-003	Sep 30, 1997	AB	RX	No	No
Teva	CLONAZEPAM	clonazepam	TABLET;ORAL	074920-001	Aug 4, 1998		DISCN	No	No
Sun Pharm Inds Inc	CLONAZEPAM	clonazepam	TABLET;ORAL	075423-001	Apr 27, 2001		DISCN	No	No
Teva	CLONAZEPAM	clonazepam	TABLET;ORAL	074569-002	Sep 10, 1996	AB	RX	No	No

Market Dynamics and Financial Trajectory for Clonazepam

Last updated: February 19, 2026

What Is the Current Status of Clonazepam?

Clonazepam is a benzodiazepine used primarily to treat panic disorders, seizure disorders, and anxiety. It was first approved by the FDA in 1975. The drug is marketed under several brand names, notably Klonopin, and is available in multiple formulations including tablets and orally disintegrating strips.

Market Size and Global Distribution

The global benzodiazepine market, including clonazepam, was valued at approximately USD 750 million in 2021. It is projected to grow at a compound annual growth rate (CAGR) of around 3.5% from 2022 to 2027. The expansion stems from increasing prevalence of anxiety and seizure-related disorders and broader approval for off-label uses.

Region	Market Share (2022)	Growth Drivers
North America	45%	High prevalence of anxiety, established healthcare access
Europe	25%	Aging population, prescription prevalence
Asia-Pacific	20%	Increasing mental health awareness, rising affluence
Rest of World	10%	Limited access, regulatory restrictions

Key Players and Market Competition

Major pharmaceutical companies producing clonazepam include Roche (Klonopin), Teva Pharmaceuticals, and Mylan. Generic versions account for over 70% of the market, driven by patent expirations. Patent exclusivity for Klonopin in the U.S. expired in 2004, opening the pathway for generics.

Company	Market Share	Product Portfolio
Teva Pharmaceuticals	35%	Generic clonazepam products
Mylan	20%	Multiple generic benzodiazepines
Roche	15%	Brand-name Klonopin
Others	30%	Small regional manufacturers

Regulatory and Prescribing Trends

Regulatory agencies have tightened controls on benzodiazepine prescriptions over recent years. In the U.S., the CDC issued guidelines in 2016 to reduce benzodiazepine overprescription, emphasizing alternative treatments for anxiety and insomnia. Despite regulatory pressure, demand persists due to a high unmet need in specific patient segments.

Patent and Market Entry Barriers

Patent expiration in the early 2000s facilitated market entry for generics. However, regulatory hurdles—such as strict prescribing guidelines and classification as a controlled substance—limit new formulations or delivery systems. Biosimilar entry is not applicable, given clonazepam's small-molecule structure.

Financial Trajectory and Revenue Forecasts

The clonazepam segment's revenue plateaued post-2010 due to generic competition and regulatory restrictions but is expected to stabilise with consistent prescription rates. Projected revenues are approximately USD 750 million globally in 2022, with modest growth over the next five years.

Year	Estimated Global Revenue (USD million)	Remarks
2022	750	Stabilized market with high generics penetration
2023	765	Slight increase from new prescription patterns
2024	780	Possible new formulations or off-label uses
2025	800	Market maturation and aging population effects
2026	815	Market reaches saturation, slow growth continues

Market Risks and Opportunities

Risks: Regulatory restrictions, risk of dependency and abuse, potential development of alternative therapies.

Opportunities: Off-label applications, novel formulations targeting specific populations, digital health monitoring integration.

Conclusion

Clonazepam's market remains sizeable but faces challenges from regulations, generics competition, and societal shifts toward non-pharmacological treatments. Financial growth is projected to remain modest, with geographic differences influencing regional revenues.

Key Takeaways

• The global market for clonazepam was valued at USD 750 million in 2021, with a CAGR of 3.5% forecast through 2027.
• Patent expiration in the early 2000s led to dominant generic manufacturing, constraining brand-name revenues.
• Regulatory restrictions have impacted prescribing practices, influencing market dynamics.
• North America and Europe account for the majority of sales, while Asia-Pacific shows growing demand.
• Revenue stability depends on off-label uses and potential formulation innovations.

FAQs

1. What factors influence clonazepam's market growth?
Prevalence of anxiety and seizure disorders, regulatory policies, availability of generics, and societal attitudes toward benzodiazepine use.

2. How does regulation impact clonazepam sales?
Stringent prescribing guidelines and controlled substance scheduling limit prescription volume and increase oversight costs.

3. Are there upcoming formulations or innovations for clonazepam?
Limited pipeline exists; most innovations relate to formulations, such as dissolvable tablets, aimed at specific patient groups.

4. What is the main competition for clonazepam?
Other benzodiazepines like diazepam and lorazepam, as well as non-benzodiazepine anxiolytics and antiepileptics.

5. What regional markets have the highest growth prospects?
Asia-Pacific and Latin America show increasing prescription rates, driven by rising mental health awareness and healthcare access improvements.

---

References

[1] Transparency Market Research. Benzodiazepines Market Size & Share. 2022.
[2] U.S. Food and Drug Administration (FDA). Clonazepam Approval History. 1975–2022.
[3] Centers for Disease Control and Prevention (CDC). Guideline for Prescribing Opioids. 2016.
[4] Market Research Future. Pharmacology of Benzodiazepines. 2021.
[5] World Health Organization. Mental Health Trends. 2020.